Medindia

X

Rhythm Control Has Similar Effect to Rate Control Drug Treatment for Mortality Chances in Atrial Fibrillation Patients

by Kathy Jones on  June 5, 2012 at 10:15 PM Heart Disease News   - G J E 4
A new study published in the Archives of Internal Medicine reveals that rhythm control is no more effective than rate control drug treatment in increasing the survival chances of patients with atrial fibrillation within the first four years after the treatment, but may provide better outcomes over a longer period.
 Rhythm Control Has Similar Effect to Rate Control Drug Treatment for Mortality Chances in Atrial Fibrillation Patients
Rhythm Control Has Similar Effect to Rate Control Drug Treatment for Mortality Chances in Atrial Fibrillation Patients
Advertisement

AF affects approximately 2.3 million Americans and 250,000 Canadians, and the condition has a complex therapy that may involve rate control agents, antiarrhythmic drugs, anticoagulant drugs and/or ablative techniques (use of a catheterization procedure to eliminate the anatomic source of the atrial fibrillation), according to study background.

Advertisement
"Controversy continues concerning the choice of rhythm control vs. rate control treatment strategies for atrial fibrillation (AF). A recent clinical trial showed no difference in five-year mortality between the two treatments. We aimed to determine whether the two strategies have similar effectiveness when applied to a general population of patients with AF with longer follow-up," the authors write as background.

Raluca Ionescu-Ittu, Ph.D., of the Harvard School of Public Health, Boston, and colleagues used population-based databases from Quebec, Canada, from 1999 to 2007 to select patients 66 years or older hospitalized with AF who did not have AF-related drug prescriptions in the year before they were hospitalized but received one within seven days of discharge.

"We found that with increasing follow-up time the mortality among the patients who newly initiated rhythm control therapy gradually decreased relative to those who initiated rate control drugs, reaching 23 percent reduction after eight years of follow-up," the authors comment.

The researchers note that recent clinical trials comparing the two treatments "concluded that there are no differences in mortality between the two treatment strategies."

"For the first four years after treatment initiation, our results in a population-based sample are similar to the results from the recent clinical trials. In addition, we found a tendency toward a long-term protective effect for rhythm control drugs. The long-term benefits of rhythm control drugs in AF found in this study need to be assessed in future studies," the researchers conclude.

(Arch Intern Med. Published online June 4, 2012. doi:10.1001/archinternmed.2012.2266. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: This research was supported by grants from the Canadian Institutes for Health Research (CIHR) to principal investigators. Some authors also disclosed support and affiliations. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Can Observational Data Trump Randomized Clinical Trial Results?

In an editorial, Thomas A. Dewland, M.D., and Gregory M. Marcus, M.D., M.A.S., of the University of California, San Francisco, write: "How do we best interpret this unexpected result given contrary evidence from prior randomized trials?"

"Although the findings of Ionescu-Ittu et al are provocative, they are insufficient to recommend a universal rhythm control strategy for all patients with AF. Randomization is a powerful tool that unfortunately cannot be reliably reproduced with statistical modeling," the authors conclude.

(Arch Intern Med. Published online June 4, 2012. doi:10.1001/archinternmed.2012.2332. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Dr. Marcus is a consultant for In-Carda Therapeutics and has received research support from St. Jude Medical, Astellas and Gilead. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To contact corresponding author Louise Pilote, M.D., M.P.H., Ph.D., call Julie Robert at 514-934-1934 ext.71381 or email julie.robert@muhc.mcgill.ca. To contact corresponding editorial author Gregory M. Marcus, M.D., M.A.S., call Leland Kim at 415-502-9553 or email leland.kim@ucsf.edu.



Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All